Document Detail

Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
MedLine Citation:
PMID:  23267145     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Early diagnosis of prostate cancer and identification of new prognostic factors remain main issues in prostate cancer research. In this study, we sought to test a panel of cancer-specific markers in urine samples as an aid for early cancer diagnosis.
MATERIALS AND METHODS: Sedimented urine samples of 66 candidates for needle biopsy were tested. Real time-polymerase chain reaction (RT-PCR) was applied to detect the expression of transmembrane protease serine-2 and Ets-related gene fusion (TMPRSS2-ERG), Ets-related gene (ERG), prostate cancer antigen-3 (PCA3), and serine peptidase inhibitor kazal type-1 (SPINK1) transcripts. For testing of the methylation status of Glutahione S-tranferase P (GSTP1) and Ras association domain family member-1(RASSF1A) promoter region, methylation-specific PCR (MSP-PCR) was applied.
RESULTS: Among the tested parameters, the presence of TMPRSS2-ERG (OR=9.044, 95% CI=2.207-37.066, p=0.002), as well as a positive test result for PCA3 (OR=7.549, 95% CI=1,858-30,672, p=0.005) were associated with the subsequent diagnosis of prostate cancer. A multivariable logistic regression including all the significantly associated variables [prostate-specific antigen (PSA), digital rectal examination (DRE), TMPRSS2-ERG and PCA3], yielded a model with area under the receiver-operating characteristic curve (AUC) =0.894 (95% CI=0.772-1.00).
CONCLUSION: A multiplexed quantitative PCR analysis on sedimented urine, in conjunction with the results of serum PSA levels and DRE, has the potential to accurately foresee subsequent needle biopsy outcomes. On the basis of the above, algorithms may be designed to guide decisions for needle biopsy.
Efthymios Dimitriadis; Theodoros Kalogeropoulos; Stamatia Velaeti; Sotirios Sotiriou; Evangelos Vassiliou; Loukas Fasoulis; Vasilios Klapsas; Michalis Synesiou; Aikaterini Apostolaki; Theoni Trangas; Nikolaos Pandis
Related Documents :
21158715 - Therapeutic nanoparticles as controlled anti-cancer medications.
21453675 - Recent advances in apoptosis, mitochondria and drug resistance in cancer cells.
16857825 - Epidermal growth factor receptor inhibitors in development for the treatment of non-sma...
21445745 - Treatment of rat bladder cancer with electrochemotherapy in vivo.
24260055 - Corosolic acid enhances the antitumor effects of chemotherapy on epithelial ovarian can...
2633635 - Experimental pancreatic cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  33     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  191-7     Citation Subset:  IM    
Department of Genetics, St. Savvas Anticancer Hospital, Alexandras Ave 171, 11522, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Induction of Death of Leukemia Cells by TW-74, A Novel Derivative of Chloro-naphthoquinone.
Next Document:  Expression Profile of Receptor Activator of Nuclear-?B (RANK), RANK Ligand (RANKL) and Osteoproteger...